Clinical findings of acquired vitelliform lesions associated with retinal pigment epithelial detachments.
OBJECTIVE
To study clinical findings associated with acquired vitelliform lesions in retinal pigment epithelial detachments (PEDs).


METHODS
Retrospective, interventional, consecutive case series.


METHODS
We retrospectively reviewed 32 eyes of 24 patients (22 men, 2 women; age range [mean], 58-85 [73.7] years) with acquired vitelliform lesions.


RESULTS
All eyes had acquired vitelliform lesions in the central macula associated with a serous PED at baseline. Of the 32 eyes, 30 (93.8%) were observed for 12 months, 26 (81.3%) for 24 months, and 17 (53.1%) for 36 months. The mean logarithm of the minimal angle of resolution best-corrected visual acuity (BCVA) levels were 0.19 at month 12, 0.28 at month 24, and 0.25 at month 36, none of which differed significantly from baseline. The mean changes in the BCVA were declines of 0.38, 1.29, and 1.21 lines at months 12, 24, and 36, respectively. Of 7 eyes treated with 3 consecutive monthly intravitreal injections of ranibizumab, the serous PEDs remained in all 7 eyes and the mean changes of BCVA were a decline of 2.40 lines 12 months after the first injection and a decline of 3.58 lines at the final visit. In the 24 untreated eyes, the mean change in the BCVA was a decline of 0.25 line at the final visit, which differed significantly (P = .021) compared with that of the treated eyes at the final visit.


CONCLUSIONS
Intravitreal injections of ranibizumab were ineffective because of the absence of resolution of the PEDs and the declines in VA.
Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan; LuEster T. Mertz Retinal Research Center, Manhattan Eye Ear and Throat Hospital and Vitreous-Retina-Macula Consultants of New York, New York, New York. Electronic address: smasaaki@fmu.ac.jp.
Masaaki
M
Saito
Department of Ophthalmology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Tomohiro
T
Iida
LuEster T. Mertz Retinal Research Center, Manhattan Eye Ear and Throat Hospital and Vitreous-Retina-Macula Consultants of New York, New York, New York.
K Bailey
KB
Freund
Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Mariko
M
Kano
LuEster T. Mertz Retinal Research Center, Manhattan Eye Ear and Throat Hospital and Vitreous-Retina-Macula Consultants of New York, New York, New York.
Lawrence A
LA
Yannuzzi
D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D015861:Retinal Neovascularization / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology; D057826:Vitelliform Macular Dystrophy / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D007208:Indocyanine Green; D000069579:Ranibizumab